Acute Prostatitis Incidence in Patients Receiving Prophylactic Ceftibuten and Gentamicin Before Prostate Biopsy

Year 2018, Volume: 8 Issue: 3, 489 - 496, 30.09.2018

Hüseyin Buğra Karakaş Engin Denizhan Demirkıran , Necmettin Aydın Mungan Bülent Akduman

https://doi.org/10.31832/smj.417804

Abstract

Abstract

Objective: We aimed to investigate the incidence and characteristics of acute prostatitis after transrectal prostate biopsy in men whom were given prophylactic ceftibuten combined with gentamicin.

Material and Methods: We analyzed the retrospective data from 245 patients who underwent transrectal ultrasound (TRUS) guided prostate biopsy over a 2 year period. Men in which acute prostatitis occured after the procedure were investigated. All patients received 400 mg ceftibuten orally once daily for 5 days, beginning 12 and 2 hours before biopsy; combined with single dose 160 mg gentamicin intramuscularly just before the procedure. All biopsies were performed as outpatient procedures.

Results: Of the 245 cases, acute prostatitis developed in 2 (0,8%). Escherichia Coli that was positive for extended spectrum β-lactamase activity was isolated both from blood and urine in 1 case. The bacteria detected in urine and blood cultures were resistant to ciprofloxacin, levofloxacin, gentamicin, cefepime, ceftriaxone and cefuroxime. However, no bacteria was isolated either from blood or urine in the other case. Both patients had acute prostatitis after the first biopsy.

Conclusion: Prophylactic ceftibuten combined with single dose gentamicin seems effective in preventing acute bacterial prostatitis after TRUS-guided prostate biopsy. Due to increasing rate of quinolone resistance among the world, alternative prophylaxis regimens including cephalosporins such as ceftibuten should be considered in men undergoing prostate biopsy. Prospective randomized trials with larger series may give more conclusive data.

Keywords

Acute bacterial prostatitis, Antibiotic prophylaxis, Ceftibuten, Core Needle Biopsy

Prostat Biyopsisi Öncesi Profilaktik Seftibuten ve Gentamisin Uygulanan Hastalarda Akut Prostatit Sıklığı

Abstract

ÖZET

Amaç: Profilaktik seftibuten, gentamisin kombinasyonu verilen erkeklerde transrektal prostat biyopsisi sonrası akut prostatitin insidansını ve özelliklerini araştırmayı amaçladık.

Gereç ve Yöntemler: Transrektal ultrasonografi (TRUS) eşliğinde prostat biyopsisi yapılan 245 hastanın 2 yıllık bir süre içinde retrospektif verileri incelendi. İşlemden sonra akut prostatit oluşan erkekler araştırıldı. Tüm hastalara biyopsiden 12 ve 2 saat önce başlamak üzere 5 gün boyunca günde bir kez 400 mg ceftibuten verildi; buna ek olarak prosedürden hemen önce, tek doz 160 mg gentamisin ile intramüsküler olarak yapılmıştır. Tüm biyopsiler ayakta tedavi prosedürü olarak gerçekleştirildi.

Bulgular: 245 olgunun 2'sinde (% 0,8) akut prostatit gelişti. Genişlemiş spektrum β-laktamaz aktivitesi pozitif olan Escherichia Coli, 1 olguda hem kan hem de idrardan izole edildi. İdrar ve kan kültürlerinde tespit edilen bakteri siprofloksasin, levofloksasin, gentamisin, sefepim, seftriakson ve sefuroksime dirençliydi. Bununla birlikte, diğer olguda kan veya idrardan hiçbir bakteri izole edilmemiştir. Her iki hastada da ilk biyopsi sonrası akut prostatit geliştiği görüldü.

Sonuç: Tek doz gentamisin ile kombine profilaktik seftibuten, TRUS kılavuzluğunda prostat biyopsisi sonrası akut bakteriyel prostatitin önlenmesinde etkili görünmektedir. Dünyada kinolon direncinin artması nedeniyle, prostat biyopsisi yapılan erkeklerde seftibuten gibi sefalosporinleri içeren alternatif profilaksi rejimleri düşünülmelidir. Bu konuda daha büyük serili prospektif randomize çalışmalar daha kesin veriler verebilir.

Keywords

Akut bakteriyel prostatit, Anitibiyotik profilaksisi, Seftibuten

References

• 1. Matlaga BR, Eskew LA, McCullough DL. Prostate biopsy: indications and technique. J Urol 2003;169:12-19.
• 2. Simardi LH, Tobias-MacHado M, Kappaz GT, Goldenstein PT, Potts JM, Wroclawski ER. Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study. Urology 2004;64:1098-101.
• 3. Serretta V, Catanese A, Daricello G, Liotta R, Allegro R, Martorana Aet al. PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. Prostate Cancer Prostatic Dis 2008;11:148-52.
• 4. Karazanashvili G, Managadze L. Prostate-specific antigen (PSA) value change after antibacterial therapy of prostate inflammation, as a diagnostic method for prostate cancer screening in cases of PSA value within 4-10 ng/ml and nonsuspicious results of digital rectal examination. Eur Urol 2001;39:538-43.
• 5. Akduman B, Akduman D, Tokgoz H, Erol B, Turker T, Ayoglu F et al. Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. Urology 2011;78:250-5.
• 6. Mosharafa AA, Torky MH, El Said WM, Meshref A. Rising Incidence of Acute Prostatitis Following Prostate Biopsy: Fluoroquinolone Resistance and Exposure Is a Significant Risk Factor. Urology 2011;78:511-4.
• 7. Minamida S, Satoh T, Tabata K, Kimura M, Tsumura H, Kurosaka S, et al. Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy. Urology 2011;78:1235-9.
• 8. Bang JH, Choe HS, Lee DS, Lee SJ, Cho YH. Microbiological characteristics of acute prostatitis after transrectal prostate biopsy. Korean J Urol 2013;54:117-22.
• 9. Otrock ZK, Oghlakian GO, Salamoun MM, Haddad M, Bizri AR al. Incidence of urinary tract infection following transrectal ultrasound guided prostate biopsy at a tertiary-care medical center in Lebanon. Infect Control Hosp Epidemiol 2004;25:873-7.
• 10. Shigehara K, Miyagi T, Nakashima T, Shimamura M. Acute bacterial prostatitis after transrectal prostate needle biopsy: clinical analysis. J Infect Chemother 2008;14:40-3.
• 11. Ho HS, Ng LG, Tan YH, Yeo M, Cheng CW. Intramuscular gentamicin improves the efficacy of ciprofloxacin as an antibiotic prophylaxis for transrectal prostate biopsy. Ann Acad Med Singapore 2009;38:212-6.
• 12. Roach MB, Figueroa TE, McBride D, George WJ, Neal DE Jr. Ciprofloxacin versus gentamicin in prophylaxis against bacteremia in transrectal prostate needle biopsy. Urology 1991;38:84-7.
• 13. Brewster SF, Mac Gowan AP, Gingell JC. Antimicrobial prophylaxis for transrectal prostatic biopsy: A prospective randomized trial of cefuroxime versus piperacillin/tazobactam. Br J Urol 1996;77:618-9.
• 14. Bosquet Sanz M, Gimeno Argente V, Arlandis Guzman S, Garcia MB, Villa T, Cruz JFJ. Comparative study between tobramicin and tobramicin plus ciprofloxacin in transrectal prostate biopsy prophylaxis. Actas Urol Esp 2006;30:866-70.
• 15. Cam K, Kayikci A, Akman Y, Erol A. Prospective assessment of the efficacy of single dose versus traditional 3-day antimicrobial prophylaxis in 12-core transrectal prostate biopsy. Int J Urol 2008;15:997-1001.
• 16. Hosokawa Y, Kishino T, Ono T, Oyama N, Momose H. Antibiotic prophylaxis for transrectal needle biopsy of the prostate. Journal of Nara Medical Association 2005;56:31-6.
• 17. Wagenlehner FM, van Oostrum E, Tenke P, Tandogdu Z, Çek M, Grabe M et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 2013;63:521-7.
• 18. Lange D, Zappavigna C, Hamidizadeh R, Goldenberg SL, Paterson RF, Chew BH. Bacterial sepsis after prostate biopsy a new perspective. Urology 2009;74:1200-5.